Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?

被引：0

作者：

Rudzki, Jakob ^{[1
]}

Wolf, Dominik ^{[1
]}

机构：

[1] Innsbruck Med Univ, Tyrolean Canc Res Ctr, A-6020 Innsbruck, Austria

来源：

EXPERT REVIEW OF HEMATOLOGY | 2011年 / 4卷 / 02期

关键词：

chronic myeloid leukemia; chronic phase; CML; high dose; imatinib; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL INHIBITOR; SUBOPTIMAL RESPONSE; MOLECULAR RESPONSES; CML PATIENTS; FOLLOW-UP; 400; MG; EUROPEAN-LEUKEMIANET; TYROSINE KINASE; MESYLATE;

D O I：

10.1586/EHM.11.9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of insufficient response but biological reasons also have to be considered. Various mechanisms of resistance have been described in the past, some of them mediating absolute resistance and others, relative resistance, to imatinib. The latter can be overcome by dose intensification of imatinib. However, the availability of second-generation tyrosine kinase inhibitors means these patients can be switched to these novel agents. Thus, which strategy is most appropriate for the individual patient with insufficient response to standard-dose imatinib remains elusive. Moreover, it remains unclear whether dose intensification of imatinib in the first-line setting might allow a more rapid and deeper response rate. This article will summarize data on imatinib dose intensification and will make recommendations about which patients imatinib dose intensification is most appropriate for.

引用

页码：153 / 159

页数：7

共 35 条

[11] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[12] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

[13] Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy [J].

Hughes, Timothy P. ;

Branford, Susan ;

White, Deborah L. ;

Reynolds, John ;

Koelmeyer, Rachel ;

Seymour, John F. ;

Taylor, Kerry ;

Arthur, Chris ;

Schwarer, Anthony ;

Morton, James ;

Cooney, Julian ;

Leahy, Michael F. ;

Rowlings, Philip ;

Catalano, John ;

Hertzberg, Mark ;

Filshie, Robin ;

Mills, Anthony K. ;

Fay, Keith ;

Durrant, Simon ;

Januszewicz, Henry ;

Joske, David ;

Underhill, Craig ;

Dunkley, Scott ;

Lynch, Kevin ;

Grigg, Andrew .

BLOOD, 2008, 112 (10) :3965-3973

[14] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) [J].

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Branford, Susan ;

Mueller, Martin C. ;

Kaeda, Jaspal S. ;

Foroni, Letizia ;

Druker, Brian J. ;

Guilhot, Francois ;

Larson, Richard A. ;

O'Brien, Stephen G. ;

Rudoltz, Marc S. ;

Mone, Manisha ;

Wehrle, Elisabeth ;

Modur, Vijay ;

Goldman, John M. ;

Radich, Jerald P. .

BLOOD, 2010, 116 (19) :3758-3765

[15] Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy [J].

Jabbour, Elias ;

Kantarjian, Hagop M. ;

Jones, Dan ;

Shan, Jenny ;

O'Brien, Susan ;

Reddy, Neeli ;

Wierda, William G. ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Verstovsek, Srdan ;

Rios, Mary Beth ;

Cortes, Jorge .

BLOOD, 2009, 113 (10) :2154-2160

[16] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[17] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, SS ;

Garcia-Manero, G ;

Verstovsek, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Letvak, L ;

Thomas, D ;

Faderl, S ;

Ferrajoli, A ;

Cortes, J .

BLOOD, 2004, 103 (08) :2873-2878

[18] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

[19] Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R) [J].

Kantarjian, Hagop ;

Pasquini, Ricardo ;

Levy, Vincent ;

Jootar, Saengsuree ;

Holowiecki, Jerzy ;

Hamerschlak, Nelson ;

Hughes, Timothy ;

Bleickardt, Eric ;

Dejardin, David ;

Cortes, Jorge ;

Shah, Neil P. .

CANCER, 2009, 115 (18) :4136-4147

[20] Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase [J].

Kantarjian, Hagop M. ;

Larson, Richard A. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Mone, Manisha ;

Rudoltz, Marc ;

Krahnke, Tillmann ;

Cortes, Jorge ;

Druker, Brian J. .

CANCER, 2009, 115 (03) :551-560

← 1 2 3 4 →